PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL

PET CT adapted treatment for first line Hodgkin Lymphoma has been widely studied in the last decades. Long-term follow-up is important to judge both efficacy and safety of this approach. Patients Methods: We analyzed updated data on all patients (pts.) treated within LH-05 GATLA trial. Newly diagnosed pts. with HL Stages I-IV were included. All received 3 ABVD evaluated a PET-CT (PET-CT+3). Pts. negative PET-CT+3 (DS 1 2) considered metabolic CR no further therapy. Pts DS 4 completed 6 IFRT positive areas. progressive disease 5) after salvage chemotherapy. With median age 35 yrs., 300 presented localized stage 190 advanced stage. long term follow up OS at 5 years 97.3% 87.3% PET+3 vs When comparing results our previous clinical trial (LH-96) there difference EFS but only 31% more than cycles compared 61% 100% LH-96. This approach reduces exposure chemo radiotherapy effect outcome. Conclusion: support stages short course ABVD. In Cox regression model, completion was most significant factor associated EFS. Treatment can be adequate regardless their diagnosis. Nevertheless, demonstrated that still room improvement trying identify will relapse escalating improve designing aim these two different risk groups. Keywords: lymphoma No conflicts interest pertinent abstract.